Form 4: Director James Brady Increases Stake in Xeris Biopharma

Director James Aloysius Brady acquired 24,193 restricted stock units and 32,996 stock options in Xeris Biopharma Holdings, Inc.

Summary

• Director James Aloysius Brady was granted 24,193 restricted stock units (RSUs) on June 4, 2026.
• The director also received a grant of 32,996 stock options with an exercise price of $6.15 per share.
• Both the RSUs and stock options are scheduled to vest in full on June 4, 2026, or upon the date of the next annual meeting of stockholders, whichever occurs first.
• Following these transactions, the director's direct beneficial ownership of common stock increased to 113,359 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Retention of key leadership personnel through standard incentive plan vesting schedules.

Negatives

• Potential for future dilution of existing shareholders upon the exercise of stock options and vesting of RSUs.

Risks

• Market price volatility affecting the value of the granted stock options.
• Dependence on continued service for the vesting of equity awards.

Future Outlook

The equity grants are subject to vesting conditions tied to continued service through the earlier of June 4, 2026, or the next annual meeting of stockholders.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices intended to align board incentives with long-term shareholder value, common among mid-cap biopharmaceutical firms.

Comparison to Industry Standards

• The use of the 2018 Stock Option and Incentive Plan is consistent with standard compensation structures for publicly traded biopharma companies.
• Vesting periods tied to annual meetings are a common industry practice for non-employee director compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution impact upon exercise of options.
• Director: Increased financial stake in the company's performance.

Next Steps

• Vesting of RSUs and stock options on June 4, 2026, or the date of the next annual meeting.

Key Dates

Keywords

Xeris Biopharma, XERS, Insider Trading, Form 4, Equity Compensation, Director Compensation